Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole Extended Release
Drug: Pramipexole Immediate Release

First Posted Date: 2007-11-14

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 156

Registration Number: NCT00558025

Locations: 🇫🇷
248.636.3307C Boehringer Ingelheim Investigational Site, Bron cedex, France
🇳🇱
248.636.31005 Boehringer Ingelheim Investigational Site, 's-hertogenbosch, Netherlands
🇫🇷
248.636.3303B Boehringer Ingelheim Investigational Site, Aix en Provence, France

and more 33 locations

Filtered Trial for Amlodipine Non-responder

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2007-11-14

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 531

Registration Number: NCT00558064

Locations: 🇯🇵
1235.13.009 Boehringer Ingelheim Investigational Site, Kiyose, Tokyo, Japan
🇯🇵
1235.13.002 Boehringer Ingelheim Investigational Site, Sendai, Miyagi, Japan
🇯🇵
1235.13.038 Boehringer Ingelheim Investigational Site, Kitaazumi-gun, Nagano, Japan

and more 38 locations

Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: matching placebo twice daily (BID)
Drug: dabigatran etexilate 150 mg twice daily (BID)

First Posted Date: 2007-11-14

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1353

Registration Number: NCT00558259

Locations: 🇺🇸
1160.63.01002 Boehringer Ingelheim Investigational Site, Laguna Hills, California, United States
🇺🇸
1160.63.01020 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
🇺🇸
1160.63.01032 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States

and more 144 locations

Cross-Sectional Study: Prevalence of Restless Legs Syndrome in Patients With Unpleasant Sensations of the Legs

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2007-11-12

Last Posted Date: 2009-02-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14956

Registration Number: NCT00557258

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Zwickau, Germany

Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2007-11-04

Last Posted Date: 2014-02-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 947

Registration Number: NCT00553267

Locations: 🇧🇬
1235.6.35904 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria
🇮🇪
1235.6.35304 Wilmer Road, Birr, Ireland
🇧🇬
1235.6.35902 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria

and more 94 locations

Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: tenofovir DF 300 mg QD
Drug: emtricitabine 200 mg QD
Drug: Nevirapine 200 mg BID
Drug: Atazanavir 300 mg
Drug: Ritonavir 100 mg

First Posted Date: 2007-11-01

Last Posted Date: 2014-01-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 154

Registration Number: NCT00552240

Locations: 🇺🇸
1100.1512.24 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇺🇸
1100.1512.20 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
🇺🇸
1100.1512.17 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States

and more 16 locations

Filtered Trial for Telmisartan 40mg Non-responder

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2007-10-30

Last Posted Date: 2014-01-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 314

Registration Number: NCT00550953

Locations: 🇯🇵
1235.14.003 Boehringer Ingelheim Investigational Site, Musashino, Tokyo, Japan
🇯🇵
1235.14.002 Boehringer Ingelheim Investigational Site, Chofu, Tokyo, Japan
🇯🇵
1235.14.004 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan

and more 2 locations

Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients

Completed

Conditions: HIV Infections

First Posted Date: 2007-10-15

Last Posted Date: 2014-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 334

Registration Number: NCT00543803

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Wuppertal, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 1, Stuttgart, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 10, Berlin, Germany

and more 13 locations

Observational Non-interventional Study With Spiriva in Chronic Obstructive Pulmonary Disease Patients With Exercise-induced Dyspnoea

Completed

Conditions: Chronic Obstructive Pulmonary Disease

First Posted Date: 2007-10-05

Last Posted Date: 2013-11-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1296

Registration Number: NCT00540163

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Zossen, Germany

Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease

Completed

Conditions: Parkinson Disease

First Posted Date: 2007-10-04

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1192

Registration Number: NCT00539214

Locations: 🇩🇪
Boehringer Ingelheim, Hellenthal, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy